Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
October 31, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Intelligent Bio Solutions has partnered with B2i Digital to execute an investor communications program.
Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results
October 29, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary...
Intelligent Bio Solutions Celebrates One Year Anniversary of Enhanced Workplace Safety with London-Based Real-Estate Developer, Mount Anvil
October 24, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
INBS announces one year of enhanced workplace safety with Mount Anvil following the integration of fingerprint drug testing.
Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek
October 14, 2024 08:00 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company offering non-invasive, rapid testing solutions,...
Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution
October 09, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
INBS announces its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency.
GPS Marine Adopts Intelligent Bio Solutions’ Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services
October 01, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
INBS announces the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts.
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
September 27, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
INBS successfully completes in-clinic testing proposed to the FDA earlier this year in its clinical study plan.
UK’s Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions’ Fingerprint Drug Test to Enhance Workplace Safety
September 25, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights
September 19, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year – - As of June 30, 2024, the Company had $6.30 million in cash - NEW...
Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Virtual Conference on September 18-19, 2024
September 11, 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a leader in non-invasive drug testing technology, today announced that its...